Oral administration of oleuropein attenuates cisplatin-induced acute renal injury in mice through inhibition of ERK signaling

Molecular Nutrition and Food Research

Volumn 60, Issue 3, 2016, Pages 530-541

  Potočnjak, Iva ^a   Škoda, Marko ^a   Pernjak Pugel, Ester ^a   Peršić, Martina Pavletić ^b   Domitrović, Robert ^a  

^a UNIVERSITY OF RIJEKA   (Croatia)

^b UNIVERSITY OF RIJEKA   (Croatia)

Author keywords

Apoptosis; Cisplatin nephrotoxicity; Inflammation; MAPK; Oleuropein

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; ENZYME INHIBITOR; IRIDOID; OLEUROPEIN; PROTECTIVE AGENT;

ACUTE KIDNEY INJURY; ANIMAL; APOPTOSIS; BAGG ALBINO MOUSE; CHEMICALLY INDUCED; DRUG EFFECTS; KIDNEY; MALE; METABOLISM; NEPHRITIS; ORAL DRUG ADMINISTRATION; OXIDATIVE STRESS; PATHOLOGY; SIGNAL TRANSDUCTION;

ACUTE KIDNEY INJURY; ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CISPLATIN; ENZYME INHIBITORS; IRIDOIDS; KIDNEY; MALE; MAP KINASE SIGNALING SYSTEM; MICE, INBRED BALB C; NEPHRITIS; OXIDATIVE STRESS; PROTECTIVE AGENTS;

EID: 84959495688     PISSN: 16134125     EISSN: 16134133     Source Type: Journal    
DOI: 10.1002/mnfr.201500409     Document Type: Article

References (53)

1. Miller, R. P., Tadagavadi, R. K., Ramesh, Reeves, W. B., Mechanisms of cisplatin nephrotoxicity. Toxins (Basel) 2010, 2, 2490-2518.
2. Chválová, K., Brabec, V., Kašpárková, J., Mechanism of the formation of DNA-protein cross-links by antitumor cisplatin. Nucleic Acids Res. 2007, 35, 1812-1821.
3. Yao, X., Panichpisal, K., Kurtzman, N., Nugent, K., Cisplatin nephrotoxicity: a review. Am. J. Med. Sci. 2007, 334, 115-124.
4. Ries, F., Klastersky, J., Nephrotoxicity induced by cancer chemotherapy with special emphasis on cisplatin toxicity. Am. J. Kidney Dis. 1986, 8, 368-379.
5. Domitrović, R., Potočnjak, I., Crnčević-Orlić, Ž., Škoda, M., Renoprotective activities of rosmarinic acid against cisplatin-induced kidney injury in mice. Food Chem. Toxicol. 2014, 66, 321-328.
6. Domitrović, R., Cvijanović, O., Pugel, E. P., Zagorac, G. B. et al., Luteolin ameliorates cisplatin-induced nephrotoxicity in mice through inhibition of platinum accumulation, inflammation and apoptosis in the kidney. Toxicology 2013, 310, 115-123.
7. Sahu, B. D., Kuncha, M., Sindhura, G. J., Sistla, R., Hesperidin attenuates cisplatin-induced acute renal injury by decreasing oxidative stress, inflammation and DNA damage. Phytomedicine 2013, 20, 453-460.
8. Sahu, B. D., Kalvala, A. K, Koneru, M., Kumar, J. M. et al., Ameliorative effect of fisetin on cisplatin-induced nephrotoxicity in rats via modulation of NF-κB activation and antioxidant defence. PLoS ONE, 2014, 9, e105070.
9. Valentovic, M. A., Ball, J. G., Mike Brown, J., Terneus, M. V. et al., Resveratrol attenuates cisplatin renal cortical cytotoxicity by modifying oxidative stress. Toxicol. In Vitro, 2014, 28, 248-257.
10. Omar, S. H., Oleuropein in olive and its pharmacological effects. Sci. Pharm. 2010, 78, 133-154.
11. Domitrović, R., Jakovac, H., Marchesi, V. V., Šain, I. et al., Preventive and therapeutic effects of oleuropein against carbon tetrachloride-induced liver damage in mice. Pharmacol. Res. 2012, 65, 451-464.
12. Pabla, N., Dong, G., Jiang, M., Huang, S. et al., Inhibition of PKCδ reduces cisplatin-induced nephrotoxicity without blocking chemotherapeutic efficacy in mouse models of cancer. J. Clin. Invest. 2011, 121, 2709-2722.
13. Kim, Y. K., Kim, H. J., Kwon, C. H., Kim, J. H. et al., Role of ERK activation in cisplatin-induced apoptosis in OK renal epithelial cells. J. Appl. Toxicol. 2005, 25, 374-382.
14. Liu, H., Baliga, R., Cytochrome P450 2E1 null mice provide novel protection against cisplatin-induced nephrotoxicity and apoptosis. Kidney Int. 2003, 63, 1687-1696.
15. Jessen, W. J., Miller, S. J., Jousma, E., Wu, J. et al., MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors. J. Clin. Invest. 2013, 123, 340-347.
16. Yanochko, G. M., Vitsky, A., Heyen, J. R., Hirakawa, B. et al., Pan-FGFR inhibition leads to blockade of FGF23 signaling, soft tissue mineralization, and cardiovascular dysfunction. Toxicol. Sci. 2013, 135, 451-464.
17. Leemans, J. C., Stokman, G., Claessen, N., Rouschop, K. M. et al., Renal-associated TLR2 mediates ischemia/reperfusion injury in the kidney. J. Clin. Invest. 2005, 115, 2894-2903.
18. 4-intoxicated mice. Toxicology 2011, 280, 33-43.
19. Domitrović, R., Cvijanović, O., Pernjak-Pugel, E., Škoda, M. et al., Berberine exerts nephroprotective effect against cisplatin-induced kidney damage through inhibition of oxidative/nitrosative stress, inflammation, autophagy and apoptosis. Food Chem. Toxicol. 2013, 62, 397-406.
20. Pabla, N., Dong, Z., Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int. 2008, 73, 994-1007.
21. Sakurai, H., Suzuki, S., Kawasaki, N., Nakano, H. et al., Tumor necrosis factor-α-induced IKK phosphorylation of NF-κB p65 on serine 536 is mediated through the TRAF2, TRAF5, and TAK1 signaling pathway. J. Biol. Chem. 2003, 278, 36916-36923.
22. Del Boccio, P., Di Deo, A., De Curtis, A., Celli, N. et al., Liquid chromatography-tandem mass spectrometry analysis of oleuropein and its metabolite hydroxytyrosol in rat plasma and urine after oral administration. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2003, 785, 47-56.
23. Serra A, Rubió L., Borràs X., Macià A. et al., Distribution of olive oil phenolic compounds in rat tissues after administration of a phenolic extract from olive cake. Mol. Nutr. Food Res. 2012, 56, 486-496.
24. Galano, A., Alvarez-Idaboy, J. R., Francisco-Márquez, M., Medina M. E., A quantum chemical study on the free radical scavenging activity of tyrosol and hydroxytyrosol. Theor. Chem. Account. 2012, 131, 1173.
25. Ozbek, E., Induction of oxidative stress in kidney. Int. J. Nephrol. 2012, 2012, 465897.
26. Liu, H., Baliga, M., Baliga, R., Effect of cytochrome P450 2E1 inhibitors on cisplatin-induced cytotoxicity to renal proximal tubular epithelial cells. Anticancer Res. 2002, 22, 863-868.
27. Valko, M., Leibfritz, D., Moncol, J., Cronin et al., Free radicals and antioxidants in normal physiological functions and human disease. Int. J. Biochem. Cell. Biol. 2007, 39, 44-84.
28. Prawan, A., Kundu, J. K., Surh, Y.-J., Molecular basis of heme oxygenase-1 induction: implications for chemoprevention and chemoprotection. Antioxid. Redox Signal. 2005, 7, 1688-1703.
29. Shiraishi, F., Curtis, L. M., Truong, L., Poss, K. et al., Heme oxygenase-1 gene ablation or expression modulates cisplatin-induced renal tubular apoptosis. Am. J. Physiol. Renal Physiol. 2000, 278, F726-F736.
30. Kang, K. P., Kim, D. H., Jung, Y. J., Lee, A. S. et al., Alpha-lipoic acid attenuates cisplatin-induced acute kidney injury in mice by suppressing renal inflammation. Nephrol. Dial. Transplant. 2009, 24, 3012-3020.
31. Sung, M. J., Kim, D. H., Jung, Y. J., Kang, K. P. et al., Genistein protects the kidney from cisplatin-induced injury. Kidney Int. 2008, 74, 1538-1547.
32. Lee, S., Kim, W., Moon, S. O., Sung, M. J. et al., Rosiglitazone ameliorates cisplatin-induced renal injury in mice. Nephrol. Dial. Transplant. 2006, 21, 2096-2105.
33. Tak, P. P., Firestein, G. S., NF-κB: a key role in inflammatory diseases. J. Clin. Invest. 2001, 107, 7-11.
34. Benedetti, G., Fredriksson, L., Herpers, B., Meerman, J. et al., TNF-α-mediated NF-κB survival signaling impairment by cisplatin enhances JNK activation allowing synergistic apoptosis of renal proximal tubular cells. Biochem. Pharmacol. 2013, 85, 274-286.
35. Jia, Z., Wang, N., Aoyagi, T., Wang, H. et al., Amelioration of cisplatin nephrotoxicity by genetic or pharmacologic blockade of prostaglandin synthesis. Kidney Int. 2011, 79, 77-88.
36. Ramesh, G., Reeves, W. B., TNF-α mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity. J. Clin. Invest. 2002, 110, 835-842.
37. Yeh, P. Y., Yeh, K. H., Chuang, S. E., Song, Y. C. et al., Suppression of MEK/ERK signaling pathway enhances cisplatin-induced NF-kappaB activation by protein phosphatase 4-mediated NF-kappaB p65 Thr dephosphorylation. J. Biol. Chem. 2004, 279, 26143-26148.
38. Scott, M. L., Fujita, T., Liou, H. C., Nolan, G. P. et al., The p65 subunit of NF-kappa B regulates I kappa B by two distinct mechanisms. Genes Dev. 1993, 7, 1266-1276.
39. Strasser, A., O'Connor, L., Dixit, V. M., Apoptosis signaling. Annu. Rev. Biochem. 2000, 69, 217-245.
40. Lee, R. H., Song, J. M., Park, M. Y., Kang, S. K. et al., Cisplatin-induced apoptosis by translocation of endogenous Bax in mouse collecting duct cells. Biochem. Pharmacol. 2001, 62, 1013-1023.
41. Liu, Y., Lu, X., Nguyen, S., Olson, J. L. et al., Epoxyeicosatrienoic acids prevent cisplatin-induced renal apoptosis through a p38 mitogen-activated protein kinase-regulated mitochondrial pathway. Mol. Pharmacol. 2013, 84, 925-934.
42. Jiang, M., Yi, X., Hsu, S., Wang, C.-Y. et al., Role of p53 in cisplatin-induced tubular cell apoptosis: dependence on p53 transcriptional activity. Am. J. Physiol. Renal Physiol. 2004, 287, F1140-F1147.
43. Wei, Q., Dong, G., Yang, T., Megyesi, J. et al., Activation and involvement of p53 in cisplatin-induced nephrotoxicity. Am. J. Physiol. Ren. Physiol. 2007, 293, F1282-F1291.
44. Cummings, B. S., Schnellmann, R. G., Cisplatin-induced renal cell apoptosis: caspase 3-dependent and -independent pathways. J. Pharmacol. Exp. Ther. 2002, 302, 8-17.
45. Chipuk, J. E., Kuwana, T., Bouchier-Hayes, L., Droin, N. M. et al., Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science 2004, 303, 1010-1014.
46. Dewson, G., Kluck, R. M., Mechanisms by which Bak and Bax permeabilise mitochondria during apoptosis. J. Cell Sci. 2009, 122, 2801-2808.
47. Arany, I., Megyesi, J. K., Kaneto, H., Price, P. M. et al., Cisplatin-induced cell death is EGFR/src/ERK signaling dependent in mouse proximal tubule cells. Am. J. Physiol. Renal Physiol. 2004, 287, F543-F549.
48. Lu, Z., Xu, S., ERK1/2 MAP kinases in cell survival and apoptosis. IUBMB Life 2006, 58, 621-631.
49. Jo, S.-K., Cho, W. Y., Sung, S. A., Kim, H. K. et al., MEK inhibitor, U0126, attenuates cisplatin-induced renal injury by decreasing inflammation and apoptosis. Kidney Int. 2005, 67, 458-466.
50. Gao, S., Chen, T., Choi, M.-Y., Liang, Y. et al., Cyanidin reverses cisplatin-induced apoptosis in HK-2 proximal tubular cells through inhibition of ROS-mediated DNA damage and modulation of the ERK and AKT pathways. Cancer Lett. 2013, 333, 36-46.
51. Kim, J., Cho, H.-J., Sagong, B., Kim, S.-J. et al., Alpha-lipoic acid protects against cisplatin-induced ototoxicity via the regulation of MAPKs and proinflammatory cytokines. Biochem. Biophys. Res. Commun. 2014, 2, 183-189.
52. Jo, S. K., Cho, W. Y., Sung, S. A., Kim, H. K. et al., MEK inhibitor, U0126, attenuates cisplatin-induced renal injury by decreasing inflammation and apoptosis. Kidney Int. 2005, 67, 458-466.
53. Domitrović, R., Potočnjak, I., Crnčević-Orlić, Ž., Škoda, M., Nephroprotective activities of rosmarinic acid against cisplatin-induced kidney injury in mice. Food Chem. Toxicol. 2014, 66, 321-328.